NCT02474186View on ClinicalTrials.gov

Phase II Study for Solid Metastatic Tumors

PHASE2CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

April 30, 2003

Primary Completion Date

July 31, 2015

Study Completion Date

July 31, 2015

Conditions
Breast CancerMetastatic Breast CancerSolid Tumor
Interventions
RADIATION

Radiation therapy

Patients with metastatic breast cancer and other metastatic solid tumors receiving single-agent chemotherapy will receive 3.5 Gy/fraction to a total dose of 35 Gy/10 fractions over 2 weeks with concurrent systemic therapy

DRUG

Xeloda

chemotherapy agent daily for two weeks

DRUG

paclitaxel

chemotherapy agent weekly for two weeks

All Listed Sponsors
lead

NYU Langone Health

OTHER

NCT02474186 - Phase II Study for Solid Metastatic Tumors | Biotech Hunter | Biotech Hunter